Stockscreener 앱 받기
48.46
0.41%
0.20
시간 외 거래:
48.46
전일 마감가:
$48.26
열려 있는:
$47.91
하루 거래량:
13.44M
Relative Volume:
0.88
시가총액:
$656.61M
수익:
$46.69B
순이익/손실:
$15.29B
주가수익비율:
14.12
EPS:
3.4329
순현금흐름:
$9.25B
1주 성능:
+5.49%
1개월 성능:
-10.87%
6개월 성능:
-24.72%
1년 성능:
-52.37%
1일 변동 폭
$47.72
$49.19
1주일 범위
$47.05
$50.43
52주 변동 폭
$45.05
$112.52
노보 노디스크 Stock (NVO) Company Profile
NVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.46 | 214.44B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,021.70 | 917.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
199.58 | 472.05B | 92.15B | 25.12B | 20.46B | 10.36 |
|
AMGN
Amgen Inc
|
341.71 | 181.33B | 35.89B | 7.01B | 11.54B | 12.94 |
|
ABBV
Abbvie Inc
|
234.00 | 410.67B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
92.86 | 230.63B | 63.90B | 19.05B | 13.05B | 7.5596 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 재개 | Jefferies | Underperform |
| 2025-10-01 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-29 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-09-16 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
Novo Nordisk Leans Into Affordability Amid Rising Competition - Benzinga
Why Is Everyone Talking About Novo Nordisk Stock? - Finviz
Trump's MAGA backlash and the GOP's scramble for an Obamacare fix: Morning Rundown - NBC News
Bernstein Remains Bullish on Novo Nordisk A/S (NVO) - Finviz
Why Novo Nordisk Stock Is Sinking This Week - Finviz
Even With Pricing and Competitive Pressure, Novo Nordisk's Portfolio Warrants a Wide Moat - Morningstar
Novo Nordisk ADR earnings missed by $0.09, revenue fell short of estimates - Investing.com Australia
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts - Sahm
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx - Sahm
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged stock rebound after recent weaknessRecession Risk & Real-Time Volume Triggers - Fundação Cultural do Pará
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal - Sahm
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates - Investing.com South Africa
Will Novo Nordisk A s (b Shares) Adrhedged stock gain from strong economyExit Point & Trade Opportunity Analysis - fcp.pa.gov.br
Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs - Sahm
Wegovy maker Novo Nordisk cuts guidance again but Medicare pricing deal uplifts investors - The Globe and Mail
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates By Investing.com - Investing.com Nigeria
$NVO Last opportunity! for NYSE:NVO by alexei_erchov - TradingView
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It - Sahm
Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House - Sahm
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb - Sahm
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle - Sahm
Bengals-Bears game today: Chicago Bears outlast Cincinnati Bengals for wild 47-42 win on Williams' TD pass to Loveland - ABC7 Chicago
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' - Sahm
Will Novo Nordisk A s (b Shares) Adrhedged stock deliver strong dividend growthExit Point & Smart Investment Allocation Tips - fcp.pa.gov.br
Can Novo Nordisk A s (b Shares) Adrhedged stock outperform in 2025 bull marketJuly 2025 Chart Watch & Fast Momentum Entry Tips - fcp.pa.gov.br
P/E Ratio Insights for Novo Nordisk - Sahm
Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk - Sahm
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
0.74%
자본화:
|
볼륨(24시간):